The global HER2 antibodies market is witnessing consistent growth, driven by the increasing prevalence of HER2-positive cancers and rapid advancements in targeted cancer therapies. Valued at US$ 9.0 billion in 2023, the market is projected to reach US$ 15.7 billion by 2034, expanding at a CAGR of 5.1% during the forecast period. The rising burden of cancers such as breast, ovarian, and gastric...